SCHEMBL4618200

SCHEMBL4618200

CCC(O)C(=O)N1CCCC1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 1/20 0.41
MMP2 P08253 1/20 0.41
MMP8 P22894 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
TDP1 Q9NUW8 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
ATM Q13315 1/20 0.38
DPP7 Q9UHL4 2/20 0.38
ALDH1A1 P00352 4/20 0.37
EPHX2 P34913 2/20 0.37
MAPT P10636 1/20 0.36
DPP4 P27487 1/20 0.36
HPGD P15428 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.35
GAA P10253 1/20 0.35
HTT P42858 1/20 0.35
CYP2C19 P33261 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4616011 1.00 MMP1 (0.41) MMP1MMP2MMP8L3MBTL1TDP1
SCHEMBL4560650 0.98 MMP1 (0.44) MMP1MMP2MMP8L3MBTL1TDP1
SCHEMBL8487636 0.83 L3MBTL1 (0.42) MMP1MMP2MMP8L3MBTL1TDP1
SCHEMBL5479224 0.81 CYP3A4 (0.50) L3MBTL1MEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL8483745 0.81 CYP3A4 (0.50) L3MBTL1MEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL12196226 0.81 CYP3A4 (0.50) L3MBTL1MEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL3549864 0.81 CYP2C19 (0.36) DPP7ALDH1A1EPHX2DPP4GAA
SCHEMBL3544356 0.81 CYP2C19 (0.36) DPP7ALDH1A1EPHX2DPP4GAA
SCHEMBL8489074 0.81 L3MBTL1 (0.44) MMP1MMP2MMP8L3MBTL1TDP1
SCHEMBL19892268 0.79 ALDH1A1 (0.52) L3MBTL1TDP1MEN1KMT2AATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080146819-A1 Process for Preparing Levetiracetam RUBAMIN LIMITED (IN) 2008-06-19 US claimed
EP-1863761-A1 PROCESS FOR PREPARING LEVETIRACETAM Rubamin Limited (IN) 2007-12-12 EP claimed
WO-2006095362-A1 PROCESS FOR PREPARING LEVETIRACETAM RUBAMIN LIMITED (IN) 2006-09-14 WO claimed
WO-2021018012-A1 IRAK4 KINASE INHIBITOR AND PREPARATION METHOD THEREFOR 珠海宇繁生物科技有限责任公司 2021-02-04 WO disclosed
US-20080194840-A1 Process for Preparing Levetiracetam and Racemization of (R)- and (S)-2-Amino Butynamide and the Corresponding Acid Derivatives RUBAMIN LABORATORIES LIMITED (IN) 2008-08-14 US disclosed
WO-2008077035-A2 PROCESSES FOR THE PREPARATION OF LEVETIRACETAM DR. REDDY'S LABORATORIES LTD. (IN) 2008-06-26 WO disclosed
US-20080146819-A1 Process for Preparing Levetiracetam RUBAMIN LIMITED (IN) 2008-06-19 US disclosed
US-20080146819-A1 Process for Preparing Levetiracetam RUBAMIN LIMITED (IN) 2008-06-19 US disclosed
EP-1879861-A2 PROCESS FOR PREPARING LEVETIRACETAM AND RACEMIZATION OF (R)- AND (S)-2-AMINO BUTYNAMIDE AND THE CORRESPONDING ACID DERIVATIVES Rubamin Laboratories Limited (IN) 2008-01-23 EP disclosed
EP-1863761-A1 PROCESS FOR PREPARING LEVETIRACETAM Rubamin Limited (IN) 2007-12-12 EP disclosed
EP-1863761-A1 PROCESS FOR PREPARING LEVETIRACETAM Rubamin Limited (IN) 2007-12-12 EP disclosed
WO-2006095362-A1 PROCESS FOR PREPARING LEVETIRACETAM RUBAMIN LIMITED (IN) 2006-09-14 WO disclosed
WO-2006095362-A1 PROCESS FOR PREPARING LEVETIRACETAM RUBAMIN LIMITED (IN) 2006-09-14 WO disclosed
EP-0828778-B1 CLATHRATE HYDRATE INHIBITOR AND METHOD OF INHIBITING THE FORMATION OF CLATHRATE HYDRATES USING IT NIPPON CATALYTIC CHEM IND (JP) 2004-05-12 EP disclosed
US-6232273-B1 MACROMOLECULAR COMPOUND WITH NITROGEN-CONTAINING RING PENDANT TO THE POLYMER CHAIN, SUCH AS POLYMER OF (METH)ACRYLOYL PYRROLIDINE, PYRROLIDINOCARBONYLETHYL (METH)ACRYLATE, 2-OXO-PYRROLIDINO-ETHYL (METH)ACRYLATE, ETC. NIPPON SHOKUBAI CO., LTD. (JP) 2001-05-15 US disclosed
US-5958837-A 2-(PHENYLMETHOXY OR CARBONYLOXY-(1,4-PHENYLENE)-),3-HALO,5-HALOALKYLPYRIDINES; HERBICIDES EFFECTING DESICCATION AND DEFOLIATION OF PLANTS; GOOD ACTIVITY AND BETTER TAILORED CONTROL OF WEEDS BASF AKTIENGESELLSCHAFT (DE) 1999-09-28 US disclosed
EP-0802904-B1 SUBSTITUTED 2-PHENYLPYRIDINES AS HERBICIDES BASF AG (DE) 1998-09-09 EP disclosed
EP-0828778-A1 CLATHRATE HYDRATE INHIBITOR AND METHOD OF INHIBITING THE FORMATION OF CLATHRATE HYDRATES USING IT NIPPON SHOKUBAI CO., LTD. (JP) 1998-03-18 EP disclosed
WO-1996038492-A1 CLATHRATE HYDRATE INHIBITOR AND METHOD OF INHIBITING THE FORMATION OF CLATHRATE HYDRATES USING IT NIPPON SHOKUBAI CO., LTD. (JP) 1996-12-05 WO disclosed
WO-1996021647-A1 SUBSTITUTED 2-PHENYLPYRIDINES AS HERBICIDES BASF AKTIENGESELLSCHAFT (DE) 1996-07-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194840-A1 Process for Preparing Levetiracetam and Racemization of (R)- and (S)-2-Amino Butynamide and the Corresponding Acid Derivatives BCAT2, ADH1C, ABAT MMP1 3504/4885MMP2 2846/4885MMP8 4165/4885
US-20080146819-A1 Process for Preparing Levetiracetam ADH1C, ADH1A, ADH5 MMP1 865/4885MMP2 1725/4885MMP8 3095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.